Losartan, Losartan/HCTZ recall manufactured by Torrent

23 de septiembre del 2019

On September 19, 2019, Torrent Pharmaceutical announced an expanded recall of specific lots of Losartan tablets (50mg and 100mg), and Losartan/hydrochlorothiazide tablets (50mg/12.5mg and 100mg/25mg) due to the detection of an unexpected impurity (NMBA) found in the active pharmaceutical ingredient.

Losartan Potassium Tablets, USP 50mg, lot # 4DU2E009, exp 12/31/2020, NDC 13668-409-10 Losartan Potassium Tablets, USP 100mg, lot# 4DU3E009, exp 12/31/2020, NDC 13668-115-90 Losartan Potassium Tablets, USP 100mg, lot # 4DU3D018, exp 02/28/2021, NDC 13668-115-10 Losartan Potassium / Hydrochlorothiazide Tablets, USP 50mg/12.5mg, lot# BEF7D051, exp 11/30/2020, NDC 13668-116-90 *Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/25mg, lot # 4P04D007, exp 07/31/2020, NDC 13668-118-90

Additional information is available on the FDA's website:

https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0

Última actualización: 13 de marzo del 2020